---
title: "국민성장펀드가 GC녹십자의 '차세대 혈액제제'에 1700억원 저리대출을 승인했다. — post author — DecisionGateway"
description: "statement by post author, recorded 2026-11-03 — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1d42b-ff51-7bc1-9a7b-0ccc36a69f7d"
meta:
  "og:description": "statement by post author, recorded 2026-11-03 — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "국민성장펀드가 GC녹십자의 '차세대 혈액제제'에 1700억원 저리대출을 승인했다. — post author — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

statementSaid on 2026-11-03

# **국민성장펀드가 GC녹십자의 '차세대 혈액제제'에 1700억원 저리대출을 승인했다.**

A statement by post author, said on 2026-11-03. Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *국민성장펀드, GC녹십자 '차세대 혈액제제' 1700억 저리대출 승인*

kgrowthPublished 2026-11-03 [ Read source](https://t.me/kgrowth/1173)

## **Related claims**

[**국민성장펀드가 1조원 규모 투자를 승인했으며 반도체 전력·장비까지 지원한다.**국민성장펀드 · statement](https://dgw.tmarket.io/claims/01a1d40f-c28d-73fb-87b3-3660deba52dd) [**8800억원 규모 국민성장펀드의 운용사 7곳이 선정되어 초장기 기술투자가 시작됐다.**한국성장금융 · statement](https://dgw.tmarket.io/claims/01a1d3fe-a655-7e47-ac6c-5238e8e2f176) [**7000억 규모 스케일업 펀드의 운용사로 IMM크레딧과 KB인베스트 등이 낙점됐다.**post author · statement](https://dgw.tmarket.io/claims/01a1d411-b829-7de2-bf03-940667cdc426) [**한국성장금융이 제2차 국민참여성장펀드 출시 관련 세부사항을 안내했다.**한국성장금융 · statement](https://dgw.tmarket.io/claims/01a1d3f7-63d2-757a-99a2-eacbd5a05ff9) [**성장금융이 딥테크 기술금융 GP를 추가 모집하며 250억을 출자한다.**성장금융 · commitment](https://dgw.tmarket.io/claims/01a1d3fa-2b20-7802-aa33-ac6e8d465abb) [**The National Growth Fund has 8 trillion won in blind funds alone and has achieved results as a priming fund for private investment.**post author · statement](https://dgw.tmarket.io/claims/01a1d404-1ea0-7797-bdb2-e9139dc7c19d)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 3,000+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1d42b-ff51-7bc1-9a7b-0ccc36a69f7d#webpage","@type":"WebPage","description":"statement by post author, recorded 2026-11-03 — verbatim quote and source citation.","name":"국민성장펀드가 GC녹십자의 '차세대 혈액제제'에 1700억원 저리대출을 승인했다. — post author — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1d42b-ff51-7bc1-9a7b-0ccc36a69f7d","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1d42b-ff51-7bc1-9a7b-0ccc36a69f7d#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1d42b-ff51-7bc1-9a7b-0ccc36a69f7d"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1d42b-ff51-7bc1-9a7b-0ccc36a69f7d#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"국민성장펀드가 GC녹십자의 '차세대 혈액제제'에 1700억원 저리대출을 승인했다.","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1d42b-ff51-7bc1-9a7b-0ccc36a69f7d#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-03","isBasedOn":"https://t.me/kgrowth/1173","text":"국민성장펀드, GC녹십자 '차세대 혈액제제' 1700억 저리대출 승인","url":"/claims/01a1d42b-ff51-7bc1-9a7b-0ccc36a69f7d"}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.